Moderna Surges 9% as Phase 3 Cancer Vaccine Data Selected for Presidential Symposium

Key Facts

In a move reflecting growing optimism toward personalized medicine innovations, Moderna shares surged 9% following the announcement that Phase 3 data for its investigational melanoma therapy was selected for a prestigious Presidential Symposium. This selection validates the results of the INTerpath-001 study, which evaluates intismeran autogene in collaboration with Merck, as the symposium slot is typically reserved for data expected to impact clinical practice.

Per market data, Moderna (MRNA) was priced at $154.04 at the close of September 18, 2026, while its partner Merck (MRK) stood at $146.76 on the same date. The stock's outperformance relative to its peers underscores the high-profile nature of the upcoming presentation, which has effectively repriced the equity around the potential success of its mRNA cancer vaccine program.

Investors should monitor current levels after the stock reached a daily high of $159.79 on September 18, 2026. The primary catalyst to watch is the scheduled presentation on October 24, where Moderna will release the full Phase 3 dataset and host an investor webcast, providing the first detailed look at the clinical results that drove the recent price action.